SBE13
SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 775294-82-1
- Formel: C24H27ClN2O4
- Molecular Weight:442.94
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
|
PLK1 200 pM (IC50) |
PLK3 875 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | EC50 |
33 μM
Compound: 38; SBE13
|
Antiproliferative activity against human A-431 cells assessed as reduction in cell proliferation incubated for 72 hrs
Antiproliferative activity against human A-431 cells assessed as reduction in cell proliferation incubated for 72 hrs
|
[PMID: 35878418] |
| A549 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| Detroit 562 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human Detroit 562 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human Detroit 562 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| HCT-15 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| HeLa | EC50 |
18 μM
Compound: 13, SBE13
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 72 hrs
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 72 hrs
|
[PMID: 25304894] |
| HeLa | EC50 |
18 μM
Compound: 38; SBE13
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| HT-29 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| LN-229 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| MCF7 | EC50 |
12 μM
Compound: 38; SBE13
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell proliferation incubated for 72 hrs
Antiproliferative activity against human MCF7 cells assessed as reduction in cell proliferation incubated for 72 hrs
|
[PMID: 35878418] |
| PC-3 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| SK-OV-3 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| SKW 6.4 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human SKW 6.4 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human SKW 6.4 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| U2OS | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
SBE13 significantly reduce cell proliferation and induce apoptosis in HeLa cells, with an EC50 of 18 μM[1]. SBE13 (1-100 μM) shows no effect on Caspase 3/7 activity in NIH-3T3 cells. SBE13 (66 and 100 μM) does not change morphology after treatment of primary cells. SBE13 (10 and 100 μM) reduces pRb staining in primary cells, and this indicates a G0/G1 arrest[2]. SBE13 (66 and 100 μM) increases levels of cyclin B1, phospho histone H3, Wee1, Emi1 and securin, and results in cleavage of Cdc27 in HeLa cells. SBE13 (10 and 100 μM) also induces apoptosis of HeLa cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 775294-82-1
-
Molecular Weight 442.94
-
Formel C24H27ClN2O4
-
SMILES
COC1=CC=C(CCNCC2=CC=C(OCC3=CC=C(Cl)N=C3)C(OC)=C2)C=C1OC
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
To assay Plk1 kinase activity, cells are lysed after 13 h release in the presence of SBE13 after double thymidine block and kinase is immunoprecipitated from lysates using antibodies. In brief, for each immunoprecipitation 800 μg of total protein are incubated with Plk1 antibody cocktail (1.5 μg) for 2 h at 4°C on a rotator. Immunoprecipitated protein is collected using Protein A/G Agarose beads. Plk1 immunoprecipitates are incubated with casein (1 μg) and with [γ-32P]ATP (1 μCi) for 30 min at 37°C in kinase buffer. Products from the kinase assays are fractionated on 10 % bis-tris-polyacrylamide gels, and phosphorylated substrate is visualized by autoradiography after an exposure of 12-36 h. Equal amounts of immunoprecipitates are subjected to Western blot analysis to confirm equal loading of Plk1 protein in kinase reactions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
Verweise
[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. [Content Brief]
[2]. Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. [Content Brief]
[3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)